P1739: HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH IBERDOMIDE PLUS DEXAMETHASONE IN A PHASE 1B/2A OPEN-LABEL DOSE ESCALATION STUDY

• N. W. van de Donk,
• S. Guo,
• L. Shi,
• J. Lord-Bessen,
• D. Tang,
• L. Karlin,
• K. Weisel,
• K. Ramasamy,
• P. C. Abad,
• A. Amin,
• S. Amin,
• S. Lonial

Affiliations

N. W. van de Donk

1 Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, Netherlands

S. Guo

2 Evidera, Waltham, MA

L. Shi

2 Evidera, Waltham, MA

J. Lord-Bessen

3 Bristol Myers Squibb, Princeton, NJ, United States of America

D. Tang

3 Bristol Myers Squibb, Princeton, NJ, United States of America

L. Karlin

4 Centre Hospitalier Lyon Sud/Hospices Civils de Lyon, Pierre-Benite, France

K. Weisel

5 University Medical Center of Hamburg-Eppendorf, Hamburg, Germany

K. Ramasamy

6 Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

P. C. Abad

3 Bristol Myers Squibb, Princeton, NJ, United States of America

A. Amin

3 Bristol Myers Squibb, Princeton, NJ, United States of America

S. Amin

3 Bristol Myers Squibb, Princeton, NJ, United States of America

S. Lonial

7 Winship Cancer Institute, Emory University, Atlanta, GA, United States of America